Company research
Pacira BioSciences, Inc.
CIK 1396814Updated Nov 6, 2026
SecurityPCRX · NASDAQ · equity
Name history
Pacira Pharmaceuticals, Inc. · through Apr 9, 2019PACIRA INC · through Nov 5, 2008Blue Acquisition Corp · through Apr 16, 2007
PCRX price & chart
Loading TradingView…
NASDAQ:PCRX on TradingView ↗About the company
Pacira BioSciences, Inc. (Nasdaq: PCRX) delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has two commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic for post-surgical pain management and ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain. Pacira is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies. Its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy, is in Phase 2 clinical development for osteoarthritis of the knee. To learn more about Pacira, visit www. Pacira.com.
In the news
PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC. ↗
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ↗
Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026 ↗
Recent filings
10-Q filing
Regulation FD Disclosure
Items 7.01, 9.01
SC 14D9/A - filed by Pacira BioSciences, Inc. regarding Pacira BioSciences, Inc.
SC 14D9 - filed by Pacira BioSciences, Inc. regarding Pacira BioSciences, Inc.
SC14D9C - filed by Pacira BioSciences, Inc. regarding Pacira BioSciences, Inc.
Show 5 more recent filings
Entry into a Material Definitive Agreement · Regulation FD Disclosure
Items 1.01, 7.01, 9.01
S-8 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Entry into a Material Definitive Agreement · Regulation FD Disclosure
Items 1.01, 7.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 1,297,577,000Source | 1,521,691,000Source | 1,243,978,000Source | 1,537,262,000Source | 1,646,820,000Source | 1,208,534,000Source | 1,586,669,000Source | 1,583,321,000Source | 1,264,917,000Source | 1,553,516,000Source | 1,574,386,000Source | 1,681,200,000Source |
| Property, Plant and Equipment, NetUSD | 147,388,000Source | 166,852,000Source | 130,277,000Source | 155,178,000Source | 168,850,000Source | 136,281,000Source | 164,451,000Source | 171,804,000Source | 140,690,000Source | 167,169,000Source | 173,927,000Source | 183,512,000Source |
| GoodwillUSD | 20,317,000Source | 0Source | 19,642,000Source | 20,300,000Source | 163,243,000Source | 19,773,000Source | 21,520,000Source | 163,243,000Source | 20,214,000Source | 0Source | 163,243,000Source | 163,243,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 382,396,000Source | 440,292,000Source | 285,484,000Source | 422,563,000Source | 454,614,000Source | 353,227,000Source | 434,969,000Source | 468,936,000Source | 368,100,000Source | 425,970,000Source | 483,258,000Source | 540,546,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 147,589,000Source | 245,965,000Source | 205,875,000Source | 300,484,000Source | 247,053,000Source | 144,306,000Source | 283,610,000Source | 184,052,000Source | 158,545,000Source | 276,774,000Source | 153,298,000Source | 104,139,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 115,268,000Source | 100,653,000Source | 132,420,000Source | 114,367,000Source | 104,779,000Source | 125,635,000Source | 104,745,000Source | 101,639,000Source | 124,069,000Source | 113,304,000Source | 105,556,000Source | 98,397,000Source |
| Inventory, NetUSD | 157,680,000Source | 111,865,000Source | 134,575,000Source | 148,163,000Source | 103,438,000Source | 150,370,000Source | 133,754,000Source | 96,782,000Source | 152,863,000Source | 125,282,000Source | 104,353,000Source | 96,063,000Source |
| Assets, CurrentUSD | 562,751,000Source | 689,969,000Source | 615,215,000Source | 745,613,000Source | 632,214,000Source | 514,961,000Source | 759,962,000Source | 543,113,000Source | 547,974,000Source | 745,130,000Source | 509,994,000Source | 498,334,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 43,469,000Source | 23,641,000Source | 29,852,000Source | 37,219,000Source | 19,771,000Source | 36,776,000Source | 27,837,000Source | 18,802,000Source | 32,618,000Source | 21,929,000Source | 21,504,000Source | 15,223,000Source |
| Operating Lease, Right-of-Use AssetUSD | 44,266,000Source | 53,830,000Source | 44,920,000Source | 46,528,000Source | 56,264,000Source | 39,409,000Source | 48,728,000Source | 58,626,000Source | 41,777,000Source | 49,222,000Source | 61,020,000Source | 70,877,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 570,363,000Source | 772,108,000Source | 572,002,000Source | 779,495,000Source | 767,542,000Source | 554,641,000Source | 788,128,000Source | 691,159,000Source | 571,806,000Source | 775,168,000Source | 704,256,000Source | 906,190,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 48,000Source | 47,000Source | 49,000Source | 48,000Source | 47,000Source | 48,000Source | 47,000Source | 47,000Source | 48,000Source | 47,000Source | 46,000Source | 46,000Source |
| Additional Paid in CapitalUSD | 1,049,545,000Source | 996,376,000Source | 1,087,452,000Source | 1,035,563,000Source | 983,178,000Source | 1,073,809,000Source | 1,023,808,000Source | 989,780,000Source | 1,064,623,000Source | 1,009,435,000Source | 976,633,000Source | 924,095,000Source |
| Retained Earnings (Accumulated Deficit)USD | -200,959,000Source | -222,397,000Source | -191,753,000Source | -206,391,000Source | -78,931,000Source | -196,406,000Source | -201,544,000Source | -97,817,000Source | -199,322,000Source | -206,356,000Source | -106,796,000Source | -148,751,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 4,123,000Source | 678,000Source | 3,241,000Source | 4,062,000Source | 105,000Source | 3,455,000Source | 1,351,000Source | 152,000Source | 4,327,000Source | 343,000Source | 247,000Source | -380,000Source |
| Stockholders' Equity Attributable to ParentUSD | 727,214,000Source | 749,583,000Source | 671,976,000Source | 757,767,000Source | 879,278,000Source | 653,893,000Source | 798,541,000Source | 892,162,000Source | 693,111,000Source | 778,348,000Source | 870,130,000Source | 775,010,000Source |
| Liabilities and EquityUSD | 1,297,577,000Source | 1,521,691,000Source | 1,243,978,000Source | 1,537,262,000Source | 1,646,820,000Source | 1,208,534,000Source | 1,586,669,000Source | 1,583,321,000Source | 1,264,917,000Source | 1,553,516,000Source | 1,574,386,000Source | 1,681,200,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 107,078,000Source | 306,401,000Source | 122,011,000Source | 313,164,000Source | 92,690,000Source | 108,787,000Source | 314,732,000Source | 93,444,000Source | 120,590,000Source | 309,920,000Source | 97,383,000Source | 147,774,000Source |
| Operating Lease, Liability, CurrentUSD | 9,748,000Source | 9,191,000Source | 10,298,000Source | 9,620,000Source | 9,149,000Source | 9,818,000Source | 9,405,000Source | 9,003,000Source | 9,839,000Source | 8,887,000Source | 8,801,000Source | 9,121,000Source |
| Accounts Payable, CurrentUSD | 17,687,000Source | 19,367,000Source | 17,509,000Source | 30,124,000Source | 18,730,000Source | 14,012,000Source | 23,172,000Source | 8,982,000Source | 15,150,000Source | 19,133,000Source | 15,698,000Source | 15,220,000Source |
| Operating Lease, Liability, NoncurrentUSD | 38,839,000Source | 47,875,000Source | 38,695,000Source | 41,291,000Source | 50,146,000Source | 33,705,000Source | 43,678,000Source | 52,446,000Source | 36,176,000Source | 44,645,000Source | 54,806,000Source | 64,802,000Source |
| Deferred Income Tax Liabilities, NetUSD | 4,587,000Source | — | 4,070,000Source | 4,583,000Source | — | 4,093,000Source | 6,996,000Source | — | 4,213,000Source | — | — | — |
| Other Liabilities, NoncurrentUSD | 25,304,000Source | 12,784,000Source | 26,650,000Source | 25,153,000Source | 13,005,000Source | 24,611,000Source | 23,866,000Source | 12,690,000Source | 20,572,000Source | 16,817,000Source | 13,573,000Source | 9,669,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 79,643,000Source | 76,377,000Source | 93,499,000Source | 71,023,000Source | 64,811,000Source | 84,957,000Source | 80,069,000Source | 66,818,000Source | 95,601,000Source | 80,124,000Source | 64,243,000Source | 89,785,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 376,721,000Source | — | 363,124,000Source | 580,492,000Source | — | 367,656,000Source | 583,376,000Source | — | 372,189,000Source | 585,321,000Source | 522,437,000Source | — |
| Long-term Debt, Current MaturitiesUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 376,721,000Source | — | 363,124,000Source | — | — | 367,656,000Source | — | — | 372,189,000Source | — | — | — |
| Short-term InvestmentsUSD | 98,745,000Source | 207,845,000Source | 45,156,000Source | 145,380,000Source | 157,173,000Source | 57,874,000Source | 210,016,000Source | 141,838,000Source | 79,879,000Source | 207,841,000Source | 125,283,000Source | 184,512,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 21,331,000Source | 21,168,000Source | 91,023,000Source | 78,785,000Source | 75,574,000Source | 91,501,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 13,539,000Source | 14,553,000Source | 57,502,000Source | 51,171,000Source | 47,895,000Source | 48,092,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 1,567,000Source | -8,559,000Source | 10,742,000Source | 7,748,000Source | 7,159,000Source | 2,079,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -2,491,000Source | 8,472,000Source | 27,567,000Source | 20,929,000Source | 8,290,000Source | -2,486,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -936,000Source | 2,464,000Source | -5,598,000Source | 3,084,000Source | 916,000Source | 6,272,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | 1,397,000Source | 6,477,000Source | 20,621,000Source | 15,615,000Source | -7,945,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 25,680,000Source | 35,459,000Source | 151,994,000Source | 189,389,000Source | 154,649,000Source | 145,274,000Source |
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | 335,000Source | 16,702,000Source | 16,702,000Source | — | 0Source | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 19,441,000Source | -25,629,000Source | 99,481,000Source | -83,276,000Source | 77,541,000Source | -225,185,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 2,724,000Source | 8,548,000Source | 15,333,000Source | 10,636,000Source | 15,161,000Source | 30,076,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 4,355,000Source | 181,000Source | 5,617,000Source | 491,000Source | 106,000Source | — |
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | 50,045,000Source | 0Source | 148,328,000Source | 25,000,000Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -59,398,000Source | -2,994,000Source | -369,627,000Source | 17,363,000Source | -183,031,000Source | -401,528,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -14,239,000Source | 6,836,000Source | -118,229,000Source | 123,476,000Source | 49,159,000Source | -481,439,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 147,589,000Source | 245,965,000Source | 205,875,000Source | 300,484,000Source | 144,306,000Source | 283,610,000Source | 158,545,000Source | 276,774,000Source | 153,298,000Source | 104,139,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 1,595,000Source | 2,715,000Source | 15,235,000Source | 15,418,000Source | 27,635,000Source | 33,295,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 50,000Source | 286,000Source | 9,013,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | 38,000Source | 0Source | -77,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 13,978,000Source | 13,230,000Source | 14,958,000Source | 15,472,000Source | 13,539,000Source | 14,553,000Source | 57,502,000Source | 51,171,000Source | 47,895,000Source | 48,092,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | 626,000Source | 840,000Source | 521,000Source | 849,000Source | 521,000Source | 845,000Source | 2,840,000Source | 3,130,000Source | 2,996,000Source | 4,400,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | 577,000Source | 867,000Source | 2,997,000Source | — | — | — |
| Amortization of Intangible AssetsUSD | — | — | 14,322,000Source | 14,322,000Source | 14,322,000Source | 14,322,000Source | 14,322,000Source | 14,322,000Source | 57,288,000Source | 57,288,000Source | 57,288,000Source | 57,288,000Source |
| DepreciationUSD | — | — | 6,900,000Source | 6,000,000Source | 7,000,000Source | 13,000,000Source | 7,000,000Source | 6,800,000Source | 33,700,000Source | 21,500,000Source | 18,300,000Source | 34,200,000Source |
| Equity Method Investment, Other than Temporary ImpairmentUSD | — | — | — | — | — | — | — | — | 11,000,000Source | 0Source | 0Source | 10,000,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | — | — | — | — | — | — | — | — | — | -193,000Source |
| Gain (Loss) on Termination of LeaseUSD | — | — | — | — | — | — | — | — | 0Source | -2,165,000Source | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | -983,000Source | 0Source | — | 0Source | — | — | -983,000Source | 7,518,000Source | -16,926,000Source | 0Source |
| GoodwillUSD | — | — | 20,317,000Source | 0Source | 19,642,000Source | 20,300,000Source | 19,773,000Source | 21,520,000Source | 20,214,000Source | 0Source | 163,243,000Source | 163,243,000Source |
| Goodwill, Impairment LossUSD | — | — | 0Source | 163,243,000Source | — | — | 163,200,000Source | — | 0Source | 163,243,000Source | — | — |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | 25,866,000Source | 0Source | — | — | — | — | 25,866,000Source | — | — | — |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | 25,866,000Source | 0Source | 0Source | 26,134,000Source |
| Income Tax Expense (Benefit)USD | — | — | 4,092,000Source | 4,610,000Source | -2,098,000Source | 2,920,000Source | 2,082,000Source | 3,894,000Source | 9,840,000Source | 36,454,000Source | 19,746,000Source | -2,607,000Source |
| InterestExpenseNonoperatingUSD | — | — | 4,279,000Source | 4,689,000Source | 3,622,000Source | 4,695,000Source | 3,699,000Source | 4,580,000Source | 17,446,000Source | 16,569,000Source | — | — |
| Investment Income, InterestUSD | — | — | 8,534,000Source | 5,482,000Source | 1,944,000Source | 5,008,000Source | 1,930,000Source | 6,895,000Source | 22,732,000Source | 19,689,000Source | 11,444,000Source | 4,542,000Source |
| LitigationSettlementLossUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 7,000,000Source | 7,000,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | 5,432,000Source | -143,466,000Source | 4,653,000Source | -4,847,000Source | 2,916,000Source | 4,812,000Source | 7,034,000Source | -99,560,000Source | 41,955,000Source | 15,909,000Source |
| Nonoperating Income (Expense)USD | — | — | 3,162,000Source | 671,000Source | -1,712,000Source | -10,426,000Source | -1,904,000Source | 6,716,000Source | -2,317,000Source | — | -25,974,000Source | -46,722,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -110,000Source | -122,000Source | -34,000Source | -10,739,000Source | -135,000Source | 4,401,000Source | -6,620,000Source | -373,000Source | -186,000Source | -11,288,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 2,000Source | 0Source | 502,000Source | 0Source | 1,939,000Source | 24,387,000Source |
| Other Operating Income (Expense), Net | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 179,516,000Source | 168,573,000Source | 192,399,000Source | 181,099,000Source | 177,376,000Source | 168,923,000Source | 726,411,000Source | — | 674,978,000Source | 666,823,000Source |
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | 91,797,000Source | 74,333,000Source | 91,809,000Source | 88,578,000Source | 93,944,000Source | 86,776,000Source | 368,759,000Source | 294,099,000Source | 269,441,000Source | 254,516,000Source |
| Operating Income (Loss)USD | — | — | 6,362,000Source | -139,527,000Source | 4,267,000Source | 8,499,000Source | 6,902,000Source | 1,990,000Source | 19,191,000Source | -73,371,000Source | 87,675,000Source | 60,024,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -110,000Source | -122,000Source | -34,000Source | -10,739,000Source | -135,000Source | 4,401,000Source | -6,620,000Source | -373,000Source | -186,000Source | -11,288,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | 9,524,000Source | -138,856,000Source | 2,555,000Source | -1,927,000Source | 4,998,000Source | 8,706,000Source | 16,874,000Source | -63,106,000Source | 61,701,000Source | 13,302,000Source |
| Income Tax Expense (Benefit)USD | — | — | 4,092,000Source | 4,610,000Source | -2,098,000Source | 2,920,000Source | 2,082,000Source | 3,894,000Source | 9,840,000Source | 36,454,000Source | 19,746,000Source | -2,607,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 5,432,000Source | -143,466,000Source | 4,653,000Source | -4,847,000Source | 2,916,000Source | 4,812,000Source | 7,034,000Source | -99,560,000Source | 41,955,000Source | 15,909,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 0.12Source | -3.11Source | 0.12Source | -0.11Source | 0.07Source | 0.1Source | 0.16Source | -2.15Source | 0.91Source | 0.35Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0.12Source | -3.11Source | 0.12Source | -0.11Source | 0.07Source | 0.1Source | 0.16Source | -2.15Source | 0.89Source | 0.34Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 44,038,000Source | 46,134,000Source | 39,462,000Source | 45,459,000Source | 40,461,000Source | 46,275,000Source | 44,566,000Source | 46,245,000Source | 46,222,000Source | 45,521,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 44,459,000Source | 46,134,000Source | 40,300,000Source | 45,459,000Source | 40,910,000Source | 46,526,000Source | 45,042,000Source | 46,245,000Source | 51,979,000Source | 46,538,000Source |
| Interest Expense (non-operating)USD | — | — | 4,279,000Source | 4,689,000Source | 3,622,000Source | 4,695,000Source | 3,699,000Source | 4,580,000Source | 17,446,000Source | 16,569,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 14,322,000Source | 14,322,000Source | 14,322,000Source | 14,322,000Source | 14,322,000Source | 14,322,000Source | 57,288,000Source | 57,288,000Source | 57,288,000Source | 57,288,000Source |
| Business Combination, Acquisition Related CostsUSD | — | — | -280,000Source | 285,000Source | 0Source | 991,000Source | 0Source | 1,511,000Source | 2,895,000Source | — | — | — |
| Costs and ExpensesUSD | — | — | 173,154,000Source | 308,100,000Source | 188,132,000Source | 172,600,000Source | 170,474,000Source | 166,933,000Source | 707,220,000Source | — | 587,303,000Source | 606,799,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 3,363,000Source | 15,833,000Source | 4,131,000Source | 5,338,000Source |
| Goodwill, Impairment LossUSD | — | — | 0Source | 163,243,000Source | — | — | 163,200,000Source | — | 0Source | 163,243,000Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | 10,497,000Source | -140,309,000Source | 5,946,000Source | -4,214,000Source | 4,167,000Source | 10,673,000Source | 19,615,000Source | -65,325,000Source | 66,257,000Source | 21,068,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 20,306,000Source | 39,976,000Source |
| Interest Expense, DebtUSD | — | — | 4,279,000Source | 4,689,000Source | 3,622,000Source | 4,695,000Source | 3,699,000Source | 4,580,000Source | 17,446,000Source | 16,569,000Source | 20,306,000Source | 39,976,000Source |
| Investment Income, InterestUSD | — | — | 8,534,000Source | 5,482,000Source | 1,944,000Source | 5,008,000Source | 1,930,000Source | 6,895,000Source | 22,732,000Source | 19,689,000Source | 11,444,000Source | 4,542,000Source |
| LitigationSettlementLossUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 7,000,000Source | 7,000,000Source | — | — | — |
| Nonoperating Income (Expense)USD | — | — | 3,162,000Source | 671,000Source | -1,712,000Source | -10,426,000Source | -1,904,000Source | 6,716,000Source | -2,317,000Source | — | -25,974,000Source | -46,722,000Source |
| Research and Development ExpenseUSD | — | — | 25,966,000Source | 19,104,000Source | 30,243,000Source | 28,200,000Source | 28,072,000Source | 25,342,000Source | 117,312,000Source | 81,577,000Source | 76,257,000Source | 84,797,000Source |
| Other Operating Income (Expense), Net | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
Filing attachments
tm2627240d1_ex99-1.htm · SC14D9C · 2026-10-08
Exhibit 99.1 Leadership resource: FAQs DEAL: What are the details of this transaction? We have entered into an agreement to be acquired. Under the agreement, Viatris has agreed to acquire all of the outstanding shares of common stock of Pacira for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion. Why is Viatris acquiring Pacira? Everything that has been built since Pacira was founded 20 years ago - and the progress we have made in recent years, from our evo…
Read attachment ↗tm2627240d1_ex99-2.htm · SC14D9C · 2026-10-08
Exhibit 99.2 Dear valued partner, Today, we announced that Pacira has entered into an agreement to be acquired by Viatris, Inc. We expect the transaction to close by the end of 2026, subject to customary closing conditions. First and foremost, this changes nothing about our commitment to you, our patients, or our mission. This agreement reinforces the value Pacira has created over two decades and the impact of our portfolio that, with your partnership, has helped more than 20 million patients…
Read attachment ↗tm2627240d2_ex99-1.htm · 8-K · 2026-10-08
Exhibit 99.1 Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies Adds Two Marketed, Patent-Protected, High-Margin Medicines in the U.S., EXPAREL® and ZILRETTA®, and Expects to Expand the Products’ Reach Across Selected Markets Within Its International Infrastructure Expands U.S. Innovative Medicines Commercial, Market Access, Medical Affairs and Global R&D Capabilities Expected to Be Syne…
Read attachment ↗ex107-ar2014inducementplan.htm · 10-K · 2026-02-26
Exhibit 10.1 PACIRA BIOSCIENCES, INC. AMENDED AND RESTATED 2014 INDUCEMENT PLAN Purpose The purpose of this Amended and Restated 2014 Inducement Plan (the “Plan”) of Pacira BioSciences, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract persons who are expected to make important contributions to the Company, by providing such persons with equity ownership opportunities and performance-based i…
Read attachment ↗ex99_1.htm · SCHEDULE 13D/A · 2026-01-02
Exhibit 99.1 DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc. Restates Position that Pacira’s Board Should Conduct Formal Sales Process of the Business Considers Current Executive Compensation and Spending Exorbitant and Unmerited Questions Whether the Board Has Exercised Appropriate Fiduciary Oversight MIAMI, FLORIDA - December 30, 2025 - DOMA Perpetual Capital Managemen…
Read attachment ↗sccrifsummer2025-ex991.htm · 8-K · 2025-07-10
EX-99.1 2 sccrifsummer2025-ex991.htm EX-99.1 Document Exhibit 99.1 On July 10, 2025, Pacira BioSciences, Inc. sent the following note to employees: Subject: Organizational Update Please take a moment to read the note below, sent on behalf of Frank D. Lee ++++++++++++ Dear Colleagues, I want to share some important news regarding organizational changes at our Science Center Campus. After very careful consideration, we have made the decision to decommission the 45-liter facility, which …
Read attachment ↗